Phase 3 N=98 18F-Fluorocholine for the Detection of Parathyroid Adenomas
Hyperparathyroidism, Primary
Primary: Proportion of True Positives for the Overall Detection of the Abnormal Parathyroid Adenoma — 0.75 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=73 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Cushing's Disease
Primary: Percentage of Randomized Participants With a Complete Response — 37; 2 Participants — p=<.0001
Phase 3 N=511 Convalescent Plasma in Outpatients With COVID-19
Covid19
Primary: Number of Patients With Disease Progression (Intention-to-treat Population) — 77; 81; 51; 56 Participants
Phase 3 N=590 A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Attention Deficit Disorder · Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42 — -12.1; -12.5; -8.07 score on a scale — p==0.0021
Phase 3 N=234 Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
Coronavirus Disease 2019 (COVID-19)
Primary: Time to Improvement in Coronavirus Disease 2019 (COVID-19) Clinical Status — 6.0; 10.5 Days — p=0.0367
Phase 3 N=23 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Osteoporosis, Postmenopausal · Osteoporosis · Osteoporosis Vertebral
Primary: Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3 — 5.74; 18.66 percentage of MS/BS — p=<0.0001
Phase 3 N=222 CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Number of Participants With AEs. — 143 Participants
Phase 3 N=500 Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
Peanut Allergy
Primary: Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population — 35.3; 13.6 percentage of participants — p=<0.001
Phase 3 N=909 Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain
Chronic Lower Back Pain · Chronic Pain
Primary: Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the Primary Timepoint Will be Week 12 of the Double-Blind Phase. — 2.7; 2.4; -0.9…
Phase 3 N=288 Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Number of Participants With AEs — 240 Participants
Phase 3 N=34 GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
Alpha1-antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution — 0; 0 Participants
Phase 3 N=87 Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD
Growth Hormone Deficiency
Primary: Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire — 29.5; 27.1 units on a scale
Phase 3 N=300 Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
Endometriosis
Primary: Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Week 12 — 98.6; 99.3 percentage of subjects
Phase 3 N=823 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC) — 162; 84; 77; 1 Participants — p=0.787
Phase 3 N=1,050 An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain
Pain, Postoperative
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 823; 73 Participants